摘要
目的:评估联合使用达格列净和磷酸西格列汀片治疗2型糖尿病患者的效果。方法:将2019年1月—2023年12月和县人民医院收治的60例2型糖尿病患者根据不同治疗方式分为对照组(n=28)和试验组(n=32)。对照组采用达格列净联合盐酸二甲双胍缓释片治疗,试验组则采用达格列净联合磷酸西格列汀片治疗。两组均进行12周治疗,比较两组临床效果、血糖水平、体重指数(BMI)、胰岛β细胞功能、血脂水平及不良反应。结果:治疗后,试验组总有效率为90.63%,高于对照组的67.86%,差异有统计学意义(P<0.05)。两组治疗后血糖水平、BMI、胰岛β细胞功能及血脂水平相较于治疗前均有显著改善,且试验组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、BMI、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、胰岛素抵抗指数(HOMA-IR)水平均低于对照组,而高密度脂蛋白胆固醇(HDL-C)、胰岛β细胞分泌指数(HOMA-β)水平均高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:联合使用达格列净和磷酸西格列汀片作为2型糖尿病治疗方案,可改善血糖控制和胰岛β细胞功能,而且具有良好的安全性。
Objective:To evaluate the efficacy of Dapagliflozin and Sitagliptin Phosphate Tablets in the treatment of patients with type 2 diabetes.Method:Sixty patients with type 2 diabetes admitted to the He County People's Hospital from January 2019 to December 2023 were divided into control group(n=28)and the experimental group(n=32)according to different treatment methods.The control group was treated with Dagaglipzin combined with Metformin Hydrochloride Sustained-release Tablets,and the experimental group was treated with Dagaglipzin combined with Sitagliptin Phosphate Tablets.Both groups were treated for 12 weeks,and the clinical effect,blood glucose level,body mass index(BMI),isletβcell function,lipid level and adverse reactions were compared between the two groups.Result:After treatment,the total effective rate of experimental group was 90.63%,which was higher than 67.86%of control group,and the difference was statistically significant(P<0.05).After treatment,blood glucose level,BMI,isletβcell function and blood lipid level in both groups were significantly improved compared with those before treatment,fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),glycated hemoglobin(HbA1c),BMI,total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and insulin resistance index(HOMA-IR)levels of the experimental group were lower than those of the control group,the levels of high density lipoprotein cholesterol(HDL-C)and isletβcell secretion index(HOMA-β)were higher than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Dagliprazin and Sitagliptin Phosphate Tablets as a treatment for type 2 diabetes,improves glycemic control and islet beta cell function,with a good safety profile.
作者
王世东
包天龙
WANG Shidong;BAO Tianlong(He County People's Hospital,He County 238200,China;不详)
出处
《中外医学研究》
2024年第19期60-63,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
达格列净
磷酸西格列汀片
2型糖尿病
不良反应
Dapagliflozin
Sitagliptin phosphate tablets
Type 2 diabetes
Adverse reactions
